SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Vlad C. Sandulache, John S. Hamblin, Heath D. Skinner, Mark W. Kubik, Jeffrey N. Myers, Jose P. Zevallos, Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma, Head & Neck, 2014, 36, 7
  2. 2
    Jill Gilbert, Ju Whei Lee, Athanassios Argiris, Missak Haigentz, Lawrence Eric Feldman, Minyoung Jang, Pattatheyil Arun, Carter Van Waes, Arlene A. Forastiere, Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group, Head & Neck, 2013, 35, 7
  3. 3
    Shousong Cao, Farukh A. Durrani, Karoly Toth, Youcef M. Rustum, Mukund Seshadri, Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts, Oral Oncology, 2011, 47, 6, 459

    CrossRef

  4. 4
    Pol Specenier, Jan B Vermorken, Advances in the systemic treatment of head and neck cancers, Current Opinion in Oncology, 2010, 22, 3, 200

    CrossRef

  5. 5
    C. H. Chung, J. Aulino, N. J. Muldowney, H. Hatakeyama, J. Baumann, B. Burkey, J. Netterville, R. Sinard, W. G. Yarbrough, A. J. Cmelak, R. J. Slebos, Y. Shyr, J. Parker, J. Gilbert, B. A. Murphy, Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Annals of Oncology, 2010, 21, 4, 864

    CrossRef